Apigenin

• Sleep onset and quality (indirect, via chamomile extract; isolated apigenin untested in humans)
• Generalized anxiety and everyday stress (chamomile RCT evidence, mixed)
• General anti-inflammatory support (preclinical NF-kB and SASP suppression)
• Longevity and healthy-aging positioning (preclinical CD38/NAD and senomorphic activity)
• Inclusion in consumer longevity and senolytic supplement stacks (marketing positioning, ahead of human trial data)

Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.

Apigenin is a naturally-occurring flavone (chemically 4',5,7-trihydroxyflavone), a yellow-pigmented polyphenol found across many plant species with substantial concentrations in parsley (the substantial dietary apigenin source, ~45mg per 100g dried parsley), chamomile (substantial chamomile tea framework, ~3-8mg per 100g dried flowers), celery (modest contribution, ~0.5mg per 100g), oranges, onions, and various other dietary sources. The substantial pharmacological positioning has evolved substantially through the 2010s-2020s from substantial chamomile herbal medicine framework (substantial sedative and anxiolytic positioning) toward substantial NAD+ preservation framework (substantial CD38 NADase inhibition) and substantial longevity/anti-aging positioning following substantial research framework development by David Sinclair laboratory at Harvard Medical School and substantial broader longevity research framework integration. The substantial primary pharmacological mechanism centers on CD38 NADase inhibition. CD38 (cluster of differentiation 38) is a transmembrane glycoprotein that functions as substantial NADase (NAD+ glycohydrolase), substantially consuming NAD+ through enzymatic hydrolysis to nicotinamide and ADP-ribose. The substantial CD38 expression increases substantially with age across multiple tissues (the substantial "inflammaging" framework), substantial age-related CD38 upregulation substantially contributes to age-related NAD+ decline. The substantial Camacho-Pereira 2016 Cell Metabolism paper from Eduardo Chini's laboratory at Mayo Clinic foundationally demonstrated substantial CD38 elevation drives substantial age-related NAD+ decline; substantial CD38 inhibition substantially restores NAD+ levels in aged mice. The substantial apigenin-CD38 inhibition framework subsequently emerged as substantial pharmacological positioning, apigenin is among the substantial flavonoid CD38 inhibitors with substantial mechanistic plausibility for substantial NAD+ preservation framework. Secondary mechanisms include substantial anti-inflammatory effects through substantial NF-κB pathway modulation, substantial COX-2 inhibition, substantial TNF-α and IL-6 reduction, and substantial broader cytokine cascade modulation. Substantial preclinical evidence supports substantial anti-inflammatory positioning across various inflammatory contexts (arthritis models, colitis models, neuroinflammation models). Substantial neuroprotective effects through substantial BDNF (brain-derived neurotrophic factor) upregulation, substantial neuroinflammation modulation, and substantial blood-brain barrier crossing (substantial apigenin BBB penetration despite substantial bioavailability challenges). Substantial cardiovascular effects through substantial endothelial function support, substantial nitric oxide modulation, and substantial modest blood pressure effects. Substantial anxiolytic and mild sedative effects through substantial GABA-A receptor modulation (the substantial chamomile herbal medicine framework foundational mechanism), apigenin binds modestly at GABA-A receptor benzodiazepine site providing substantial modest anxiolytic effect. Substantial estrogen receptor modulation through substantial weak phytoestrogen activity, substantial complex estrogen receptor alpha and beta interactions; substantial dose-dependent and tissue-dependent effects. Limited clinical relevance at typical supplementation doses; substantial coordination consideration for users with hormone-sensitive conditions (substantial breast cancer, substantial endometriosis, others) is reasonable rather than substantial categorical concern. Substantial anti-cancer preclinical evidence, substantial in vitro and in vivo evidence across various cancer cell lines and animal models. Substantial multiple mechanisms including substantial apoptosis induction, substantial cell cycle modulation, substantial angiogenesis inhibition, and substantial chemoprevention positioning. The substantial preclinical-to-clinical translation remains substantially limited; substantial dietary apigenin intake has been associated with substantial modest cancer risk reduction in some epidemiological frameworks (substantial Mediterranean diet adherence with substantial parsley intake contributions). The substantial bioavailability profile presents substantial challenges. Apigenin has substantial low water solubility (~2.5 µg/mL), substantial poor oral absorption (~2-5% bioavailability), substantial extensive Phase II metabolism (substantial glucuronidation, sulfation), and substantial substantial gut microbial metabolism producing substantial bioactive metabolites (the substantial gut microbiome-flavonoid interaction creates substantial individual variability). The substantial apigenin glucuronide and sulfate conjugates produced through Phase II metabolism are themselves bioactive in many contexts; substantial systemic apigenin exposure substantially reflects substantial conjugated metabolite framework rather than substantial free apigenin alone. The substantial sustained-release formulations (liposomal, phytosome, micronized) may modestly improve bioavailability; substantial commercial framework has emerged for substantial advanced delivery technologies. The substantial commercial supplement category has expanded substantially through the 2020s. Substantial Renue By Science (apigenin liposomal positioning), Double Wood (mainstream apigenin), Life Extension (apigenin combination products), and various other brands provide substantial commercial availability. The substantial Bryan Johnson Blueprint protocol inclusion (50mg apigenin daily) reflects substantial premium consumer longevity protocol category positioning. The substantial dietary positioning through parsley intake (~45mg per 100g dried parsley substantially exceeds typical supplement dosing) provides substantial dietary supplementation alternative. The substantial chamomile tea heritage provides substantial traditional supplementation framework with substantial nutritional matrix advantage. The substantial pharmaceutical category remains essentially absent, apigenin positioned exclusively as dietary supplement and herbal medicine framework without substantial pharmaceutical category development through 2025.

Apigenin supplementation is typically dosed at 50-200mg daily depending on application and brand framework. The substantial Bryan Johnson Blueprint protocol uses 50mg daily, substantial premium consumer longevity protocol category positioning. Substantial mainstream supplement category dosing typically reflects substantial 50-100mg daily through standard capsule format with substantial bioavailability limitations. Substantial liposomal and phytosome formulations may use substantial lower dosing (25-100mg) with substantial bioavailability enhancement claims; clinical translation evidence for substantial bioavailability advantage remains limited. Take with or without food, apigenin absorption is reasonable either way, though substantial concurrent fat intake may modestly enhance absorption given substantial low water solubility profile. Many users prefer morning dosing as part of routine longevity protocol integration; substantial evening dosing may be reasonable for users seeking substantial mild anxiolytic effect through substantial GABA-A receptor modulation. Substantial sustained daily supplementation matters more than acute dosing, substantial NAD+ preservation and substantial broader longevity mechanisms operate through sustained cellular metabolic signaling rather than acute pharmacological effect. Substantial supplementation duration matters, meaningful effects likely require substantial sustained supplementation over months-to-years. Dietary apigenin intake provides substantial supplementation alternative or complement. Substantial dietary apigenin through parsley (~45mg per 100g dried, ~4-5mg per 100g fresh), chamomile (substantial chamomile tea framework), celery, oranges, onions can substantially complement or exceed typical supplement dosing. Substantial dietary positioning advantage through nutritional matrix, substantial cofactor polyphenol contributions and broader nutrient framework. Substantial Mediterranean diet adherence with substantial parsley consumption provides substantial dietary supplementation framework. Substantial chamomile tea (1-3 cups daily) provides substantial traditional supplementation framework. The drug interaction profile is modest for most users. Substantial GABA-A receptor modulation creates substantial mild interaction with benzodiazepines, alcohol, and broader CNS depressants; substantial mild antiplatelet effects warrant substantial INR monitoring for warfarin users. Substantial weak phytoestrogen activity creates substantial coordination consideration for hormone-sensitive conditions (breast cancer history, endometriosis); substantial individual coordination essential rather than blanket avoidance. The substantial anti-cancer preclinical evidence supports substantial supplementation framework for general adults; substantial active cancer or recent cancer history warrants substantial specialist oncology coordination. Pregnancy and lactation: limited safety data for substantial supplementation; substantial dietary intake generally considered safe. Substantial chamomile tea has substantial traditional safe consumption framework. Pediatric use: substantial supplementation not appropriate without pediatrician coordination. The substantial bioavailability limitations create substantial individual variability, substantial gut microbiome composition substantially affects systemic apigenin exposure; substantial sustained supplementation may produce substantial individual response variability. The substantial substantial Bryan Johnson Blueprint protocol inclusion reflects substantial premium consumer longevity protocol category positioning; substantial mainstream alternatives provide substantial accessibility at substantially lower price point. Substantial dietary approach as foundational framework with supplements as substantial supplement reflects substantial reasonable supplementation philosophy.

Standard supplementation

50-200mg daily

Bryan Johnson Blueprint

50mg daily

Liposomal formulations

25-100mg daily (claimed bioavailability advantage)

Dietary intake through parsley

5-50mg achievable (parsley-rich diet)

Chamomile tea framework

1-3 cups daily (traditional)

Take with

With or without food; modest fat enhancement

Bioavailability

Low (~2-5%) standard capsule format

Sustained supplementation duration

Months-to-years for substantial longevity effects

• Standard Apigenin Capsules (50-100mg)

  Rating: gold

  The substantial standard apigenin supplement format, typically 50-100mg per capsule. Substantial Bryan Johnson Blueprint protocol uses 50mg daily; substantial broader supplement category typically uses 50-200mg daily dosing. Substantial bioavailability limitations apply to all standard capsule formats.

• Liposomal Apigenin (Advanced Delivery)

  Rating: gold

  Substantial liposomal apigenin formulations (Renue By Science, Quicksilver Scientific, others) using substantial phosphatidylcholine encapsulation for substantial bioavailability enhancement. Substantial premium positioning; substantial bioavailability advantage versus standard capsule format though clinical translation evidence remains limited. Substantial higher pricing per dose.

• Apigenin Phytosome / Phospholipid Complex

  Rating: good

  Substantial phytosome technology bound apigenin formulations using substantial soy phosphatidylcholine complexing. Substantial modest bioavailability enhancement versus standard capsule format. Substantial commercial category positioning.

• Bryan Johnson Blueprint Apigenin Protocol

  Rating: gold

  Substantial premium consumer longevity protocol inclusion, 50mg apigenin daily as part of comprehensive Bryan Johnson Blueprint anti-aging protocol. Substantial mainstream consumer adoption demonstration.

• Dietary Apigenin Through Whole Foods

  Rating: gold

  Substantial dietary apigenin intake through parsley (~45mg per 100g dried, ~4-5mg per 100g fresh), chamomile (substantial chamomile tea framework, ~3-8mg per 100g dried flowers), celery (~0.5mg per 100g), oranges, onions, and various other sources. Substantial Mediterranean diet positioning advantage through substantial parsley consumption, substantial dietary positioning advantage through nutritional matrix versus isolated supplementation.

• Chamomile Tea (Traditional Herbal Framework)

  Rating: gold

  Substantial traditional chamomile tea framework providing substantial apigenin contribution alongside substantial broader chamomile phytochemical complement (matricin, chamazulene, alpha-bisabolol, others). Substantial traditional herbal medicine inheritance; substantial anxiolytic and sleep-supporting positioning. Substantial substantial dietary apigenin intake through routine chamomile tea consumption (substantial 1-3 cups daily framework).

• Renue By Science Liposomal Apigenin

  Rating: good

  Substantial commercial liposomal apigenin positioning with substantial bioavailability enhancement framework. Premium category positioning; substantial direct-to-consumer marketing. ~25-50mg per dose typical.

• Double Wood Apigenin

  Rating: good

  Substantial mainstream apigenin supplement at substantially lower price point than premium alternatives. Reasonable consumer choice for users seeking apigenin supplementation without substantial premium pricing commitment.

• Adults pursuing comprehensive longevity supplementation protocols

  Strength of evidence for this group: modest

  Substantial NAD+ preservation framework provides substantial supplementation rationale for adults pursuing comprehensive longevity protocol integration. Substantial CD38 inhibition mechanism complements substantial NAD+ precursor framework (NMN, NR), substantial NAD+ precursors support synthesis; substantial CD38 inhibition (apigenin) reduces NAD+ degradation. Substantial complementary mechanism integration.

• Adults with anxiety or sleep concerns

  Strength of evidence for this group: cautious

  Substantial chamomile herbal medicine framework supports substantial mild anxiolytic positioning through substantial GABA-A receptor modulation. Substantial Amsterdam 2009 chamomile RCT demonstrated substantial anxiolytic effect in generalized anxiety. Modest effect sizes; reasonable supplementation framework as adjunct to comprehensive anxiety/sleep management.

• Adults with anti-inflammatory concerns

  Strength of evidence for this group: cautious

  Substantial anti-inflammatory mechanism through substantial NF-κB pathway modulation, substantial COX-2 inhibition, and substantial broader cytokine cascade modulation. Substantial preclinical evidence; limited human clinical trial evidence for substantial inflammatory disease applications. Reasonable supplementation framework as adjunct to comprehensive anti-inflammatory management.

• Adults with cardiovascular concerns

  Strength of evidence for this group: cautious

  Substantial preclinical cardiovascular evidence through substantial endothelial function support, substantial nitric oxide modulation, and substantial modest blood pressure effects. Limited human clinical trial evidence. Reasonable supplementation framework as adjunct to comprehensive cardiovascular management.

• Adults with neuroprotective interests

  Strength of evidence for this group: cautious

  Substantial preclinical neuroprotection evidence through substantial blood-brain barrier crossing, substantial BDNF upregulation, and substantial neuroinflammation modulation. Limited human clinical trial evidence for substantial neuroprotective applications. Reasonable supplementation framework for substantial cognitive aging concerns; calibrated expectations.

• Adults pursuing dietary apigenin through whole foods

  Strength of evidence for this group: modest

  Substantial dietary apigenin intake through parsley, chamomile tea, celery, oranges, onions provides substantial whole-foods supplementation framework with substantial nutritional matrix advantage. Substantial dietary positioning advantage through cofactor polyphenol contributions and broader nutrient framework. Reasonable dietary approach as foundational framework with supplements as substantial supplement.

• Adults with hormone-sensitive conditions (caution)

  Strength of evidence for this group: cautious

  Substantial weak phytoestrogen activity through substantial complex estrogen receptor alpha and beta interactions. Limited clinical relevance at typical supplementation doses; substantial coordination consideration for users with hormone-sensitive conditions (substantial breast cancer history, substantial endometriosis, others) is reasonable. Specialist coordination essential for substantial hormone-sensitive contexts.

• Adults with cancer history (caution)

  Strength of evidence for this group: cautious

  Substantial anti-cancer preclinical evidence; substantial preclinical chemoprevention positioning. Substantial individual cancer type variability; substantial coordination essential for users with active or recent cancer history. Substantial phytoestrogen activity adds substantial complexity for hormone-sensitive cancers.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  Limited human pregnancy safety data; substantial phytoestrogen activity adds substantial coordination context. Substantial dietary intake through routine parsley, chamomile, celery consumption generally considered safe; substantial supplementation framework warrants specialist OB-GYN coordination. Substantial chamomile tea generally considered safe in moderate consumption.

• Pediatric use

  Strength of evidence for this group: cautious

  Limited pediatric safety data for substantial supplementation; substantial dietary intake through whole foods generally considered safe. Substantial chamomile tea has substantial traditional pediatric use framework but pediatrician coordination reasonable for substantial regular use. Substantial supplementation framework not appropriate without pediatrician coordination.

• Adults on benzodiazepines or other CNS depressants

  Strength of evidence for this group: cautious

  Substantial GABA-A receptor modulation creates substantial theoretical interaction with benzodiazepines, alcohol, and broader CNS depressants. Substantial mild interaction at typical supplement doses; substantial coordination reasonable.

• Adults on anticoagulants

  Strength of evidence for this group: cautious

  Substantial modest antiplatelet effects through substantial flavonoid platelet modulation. Substantial mild interaction at typical supplement doses; substantial INR monitoring reasonable for warfarin users.

• NMN, NR (NAD+ precursors)

  Interaction: synergy

  Substantial NAD+ preservation framework synergy, NAD+ precursors (NMN, NR) support substantial NAD+ synthesis; apigenin inhibits CD38 NADase to substantially reduce NAD+ degradation. Substantial complementary mechanism integration for substantial NAD+ maintenance.

• Spermidine (Autophagy Inducer)

  Interaction: synergy

  Substantial complementary longevity framework, spermidine induces autophagy; apigenin preserves NAD+ levels. Different but substantially complementary cellular maintenance frameworks. Substantial longevity polyphenol cluster integration.

• Resveratrol, Pterostilbene (Sirtuin Activators)

  Interaction: synergy

  Substantial complementary longevity polyphenol framework, sirtuin activators support NAD+-dependent deacetylase activity; apigenin preserves NAD+ levels for sirtuin substrate availability. Substantial complementary mechanism integration.

• Quercetin, Fisetin (Senolytic Flavonoids)

  Interaction: synergy

  Substantial flavonoid cluster integration, quercetin and fisetin function as substantial senolytic agents; apigenin functions as CD38 inhibitor and anti-inflammatory flavonoid. Substantial complementary flavonoid framework integration.

• Curcumin, Boswellia (Anti-inflammatory)

  Interaction: synergy

  Substantial complementary anti-inflammatory framework, different but substantially complementary anti-inflammatory pathway modulation. Substantial broader longevity and anti-inflammatory framework integration.

• Coenzyme Q10, PQQ (Mitochondrial Support)

  Interaction: synergy

  Substantial complementary mitochondrial framework, substantial CoQ10 and PQQ support mitochondrial function; apigenin supports substantial cellular metabolic framework. Substantial complementary cellular energy framework.

• Chamomile Tea (Traditional Herbal Framework)

  Interaction: synergy

  Substantial traditional chamomile tea framework provides substantial apigenin contribution alongside substantial broader chamomile phytochemical complement. Substantial complementary or substitution framework for supplemental apigenin.

• Mediterranean Dietary Pattern

  Interaction: synergy

  Substantial Mediterranean dietary pattern with substantial parsley, oregano, celery, oranges, onions intake provides substantial dietary apigenin framework. Substantial dietary positioning advantage through nutritional matrix.

• Benzodiazepines (Anti-anxiety/Sleep)

  Interaction: caution

  Substantial GABA-A receptor modulation creates substantial theoretical additive sedative effect with benzodiazepines. Substantial mild interaction at typical supplement doses; substantial coordination reasonable for benzodiazepine users.

• Alcohol (Substantial GABA Modulator)

  Interaction: caution

  Substantial GABA-A receptor modulation creates substantial theoretical additive sedative effect with alcohol. Substantial mild interaction at typical supplement doses; substantial moderation reasonable.

• Anticoagulants (Warfarin, DOACs, Antiplatelets)

  Interaction: caution

  Substantial modest antiplatelet effects through substantial flavonoid platelet modulation. Substantial mild interaction at typical supplement doses; substantial INR monitoring for warfarin users.

• Tamoxifen, Aromatase Inhibitors

  Interaction: caution

  Substantial weak phytoestrogen activity creates substantial theoretical interaction with hormone modulation therapies for breast cancer. Substantial coordination essential for users on hormone-targeted cancer therapies.

• Hormone-Sensitive Cancer History

  Interaction: caution

  Substantial weak phytoestrogen activity creates substantial coordination context for users with hormone-sensitive cancer history (breast, endometrial, ovarian). Specialist oncology consultation essential.

• Pregnancy and Lactation

  Interaction: caution

  Substantial phytoestrogen activity adds substantial coordination context for supplementation. Substantial dietary intake generally considered safe; substantial chamomile tea has substantial traditional safe consumption framework. Specialist OB-GYN coordination for substantial supplementation.

Look for: explicit apigenin content per serving (typically 50-100mg per supplement capsule for standard format; 25-100mg for liposomal/phytosome formulations); substantial standardization specification (typically 95%+ apigenin in commercial extracts); reputable manufacturer with substantial quality control disclosure; bioavailability enhancement technology disclosure (liposomal, phytosome) where relevant. Avoid: products without specific apigenin content disclosure; aggressive marketing claims about specific longevity outcomes that exceed evidence base; very low-cost alternatives that may not maintain apigenin content; impulse purchasing based on Sinclair Lab or Bryan Johnson Blueprint association without ingredient evaluation. Substantial dietary apigenin through parsley intake and chamomile tea provides substantial alternative or complementary framework, substantial dietary positioning advantage through nutritional matrix.

Apigenin biology developed substantially through the 20th century with substantial flavonoid biology framework development. The substantial flavone class of polyphenols was characterized substantially through substantial mid-century natural products chemistry; substantial isolation from parsley, chamomile, and various other plant sources established substantial foundational understanding. The substantial flavonoid bioavailability framework developed substantially through the 1990s-2000s with substantial characterization of substantial low water solubility, substantial poor oral bioavailability, substantial extensive Phase II metabolism, and substantial gut microbial metabolism. The substantial chamomile herbal medicine framework provides substantial traditional supplementation context, substantial chamomile use across European, Mediterranean, and Middle Eastern traditional medicine for substantial mild sedative, anxiolytic, anti-inflammatory, and digestive applications across substantial centuries. The substantial Amsterdam 2009 randomized controlled trial provided substantial modern clinical evidence support for substantial chamomile anxiolytic positioning. The substantial CD38 NADase framework emerged substantially through the 2010s with substantial Camacho-Pereira 2016 Cell Metabolism foundational paper from Eduardo Chini's laboratory at Mayo Clinic demonstrating substantial CD38 elevation drives substantial age-related NAD+ decline. The substantial Escande 2013 Diabetes paper from the same lab characterized substantial CD38 inhibitors including apigenin as substantial flavonoid CD38 inhibitor framework. The substantial mechanistic framework positioned apigenin within substantial broader longevity research framework integration. The substantial David Sinclair Harvard Medical School research framework integration through 2010s-2020s positioned apigenin within substantial broader NAD+/sirtuin/longevity framework alongside substantial NMN, NR, resveratrol, and broader research framework. The substantial premium consumer longevity protocol category positioning developed substantially through the 2020s with substantial Bryan Johnson Blueprint protocol inclusion (50mg daily apigenin) substantially driving substantial mainstream consumer awareness. The substantial commercial supplement category developed substantially through the 2020s. Substantial Renue By Science liposomal positioning, Double Wood mainstream positioning, Life Extension combination product positioning, and various other commercial frameworks emerged. The substantial bioavailability challenge drove substantial advanced delivery technology development (liposomal, phytosome formulations); substantial clinical translation evidence for substantial bioavailability advantage remains limited. The substantial regulatory framework, apigenin remains positioned exclusively as dietary supplement under DSHEA framework in United States and equivalent European framework; substantial chamomile tea has substantial traditional food framework. Substantial pharmaceutical category remains essentially absent, apigenin not pursued for substantial pharmaceutical development through 2025 despite substantial mechanistic interest. The modern consumer market has expanded substantially through the 2020s with substantial Bryan Johnson Blueprint protocol consumer awareness driving substantial mainstream apigenin supplementation framework adoption. The substantial dietary apigenin framework (substantial parsley, chamomile tea, celery, oranges, onions) provides substantial whole-foods supplementation alternative. The substantial Mediterranean dietary pattern adherence with substantial parsley consumption provides substantial dietary supplementation framework. The substantial broader longevity research framework integration continues to mature, substantial NAD+ precursor framework with NMN/NR; substantial sirtuin activator framework with resveratrol/pterostilbene; substantial autophagy induction framework with spermidine; substantial senolytic framework with quercetin/fisetin; substantial CD38 inhibition framework with apigenin. Substantial systems biology positioning for substantial future research framework development.

1. 20th centuryFlavonoid biology and natural products chemistry foundational development
2. Traditional / centuriesChamomile herbal medicine framework across European, Mediterranean, Middle Eastern traditions
3. 1990s-2000sSubstantial flavonoid bioavailability framework development
4. 2009Amsterdam chamomile anxiolytic RCT
5. 2013Escande Diabetes CD38 inhibitor characterization including apigenin
6. 2014USDA flavonoid database (Bhagwat) dietary apigenin characterization
7. 2016Camacho-Pereira Cell Metabolism CD38 NAD+ decline framework
8. 2010s-2020sDavid Sinclair Harvard research framework integration
9. 2020sBryan Johnson Blueprint protocol consumer awareness (50mg daily)
10. 2020sSubstantial commercial supplement category development (Renue By Science, Double Wood, Life Extension)

• Whether substantial human clinical evidence will mature to support substantial apigenin longevity applications beyond substantial preclinical and mechanistic evidence base.
• Whether substantial CD38 inhibition at supplement doses provides clinically meaningful NAD+ preservation in humans or whether substantial dose limitations restrict substantial clinical effect.
• Whether substantial bioavailability enhancement formulations (liposomal, phytosome) translate substantial bioavailability advantage to substantial clinical outcome advantage.
• Whether substantial dietary apigenin intake provides substantially equivalent or superior benefit versus isolated supplement format.
• Whether substantial Bryan Johnson Blueprint protocol consumer adoption will drive substantial broader category awareness and substantial mainstream supplementation framework adoption.
• Whether substantial phytoestrogen activity creates substantial clinical concerns for hormone-sensitive contexts or remains substantial theoretical consideration without substantial clinical impact at supplement doses.
• Whether substantial gut microbiome variability creates substantial individual response variability in apigenin supplementation outcomes.
• Whether substantial chamomile tea framework provides substantially equivalent apigenin supplementation benefit versus isolated apigenin supplement format.
• Whether substantial anti-cancer preclinical evidence will mature to support substantial cancer prevention applications.
• How substantial NAD+ preservation framework will mature within broader longevity research framework integration (NMN/NR precursors, sirtuin activators, broader polyphenol framework).

Widely available globally through direct-to-consumer (Renue By Science, Quicksilver Scientific, ProHealth Longevity, others), Amazon, mainstream supplement retailers (GNC, Vitamin Shoppe, Whole Foods supplement sections), and various specialty longevity supplement channels. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pricing: $20-80/month depending on brand positioning, dose, and bioavailability format, substantial premium pricing for liposomal positioning (~$50-80/month); substantial mid-tier pricing for mainstream supplements (~$20-40/month). Substantial dietary apigenin through parsley intake and chamomile tea provides substantial supplementation alternative at substantially lower cost. The substantial Bryan Johnson Blueprint protocol inclusion (50mg daily) reflects substantial premium consumer longevity protocol category positioning. The substantial David Sinclair Harvard research framework integration provides substantial pharmacological credibility through substantial CD38 inhibition mechanism positioning. The substantial Eduardo Chini Mayo Clinic CD38 research framework provides substantial mechanistic foundation. The substantial pharmaceutical category remains essentially absent, apigenin positioned exclusively as dietary supplement and herbal medicine framework. Substantial chamomile tea provides substantial accessible substantial traditional supplementation framework with substantial nutritional matrix advantage. Substantial parsley dietary intake provides substantial dietary positioning framework. The substantial gut microbiome variability creates substantial individual response variability, substantial sustained supplementation may produce substantial individual variability outcomes. Substantial Renue By Science liposomal positioning, Double Wood mainstream positioning, Life Extension combination product positioning, and various other commercial frameworks provide substantial market variation.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Class A, extracted flavone polyphenol

Chemical name

4',5,7-trihydroxyflavone

Primary mechanism

CD38 NADase inhibition → NAD+ preservation

Standard daily dose

50-200mg

Bryan Johnson Blueprint

50mg daily

Bioavailability

Low (~2-5%) standard capsule format

What follows is unfinished work on our side, not a finding about Apigenin. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.